Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015-December 2019
Por:
Merdrignac L, Aït El Belghiti F, Pandolfi E, Acosta L, Fabiánová K, Habington A, García Cenoz M, Bøås H, Toubiana J, Tozzi AE, Jordán-García I, Zavadilová J, O'Sullivan N, Navascués A, Flem E, Croci I, Jané M, Krížová P, Cotter S, Fernandino L, Bekkevold T, Munoz-Almagro C, Bacci S, Kramarz P, Kissling E and Savulescu C
Publicada:
2 abr 2024
Ahead of Print:
1 abr 2024
Resumen:
Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/ he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. Conclusions: Our results suggest moderate one -dose and two -dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
Filiaciones:
Merdrignac L:
Epidemiology Department, Epiconcept, Paris, France
Aït El Belghiti F:
Direction des maladies infectieuses, Santé Publique France, Paris, France
Pandolfi E:
Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
Acosta L:
Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain
Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain
Fabiánová K:
National Institute of Public Health, Prague, Czech Republic
Habington A:
Children's Health Ireland, Crumlin, Dublin, Ireland
García Cenoz M:
Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
Bøås H:
Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
Toubiana J:
Biodiversité et Epidémiologie des bactéries et pathogènes, Institut Pasteur, Paris, France
National Reference Center for Whooping Cough and Other Bordetella Infections, Institut Pasteur, Paris, France
Tozzi AE:
Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
Jordán-García I:
Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
University of Barcelona, Barcelona, Spain
Zavadilová J:
National Institute of Public Health, Prague, Czech Republic
O'Sullivan N:
Children's Health Ireland, Crumlin, Dublin, Ireland
Navascués A:
Hospital Universitario Navarra, Pamplona
Flem E:
Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
Croci I:
Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
Jané M:
Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
University of Barcelona, Barcelona, Spain
Krížová P:
National Institute of Public Health, Prague, Czech Republic
Cotter S:
Health Protection Surveillance Centre, Dublin, Ireland
Fernandino L:
Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
Bekkevold T:
Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
Munoz-Almagro C:
Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain
Bacci S:
European Centre for Diseases Control and Prevention, Stockholm, Sweden
Kramarz P:
European Centre for Diseases Control and Prevention, Stockholm, Sweden
Kissling E:
Epidemiology Department, Epiconcept, Paris, France
Savulescu C:
Epidemiology Department, Epiconcept, Paris, France
Green Submitted, hybrid
|